ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,064.20
0.91%
Dow Jones
38,225.66
0.85%
US Dollar vs MXN
16.98307
0.06%
Brent Oil
83.845
0.26%
Bitcoin
59,633.14
0.87%
Registration Strip Icon for default Regístrate gratis para obtener cotizaciones en tiempo real, gráficos interactivos, flujo de opciones en vivo y más.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. Addex Therapeutics Ltd (ADXN)

  7. Addex Therapeutics Ltd (ADXN) Noticias

ADXN Addex Therapeutics Ltd

8.85
0.7399 (9.12%)
02 May 2024 - Cerrado
Retrasado por 15 minutos
Nombre de la Acción Símbolo de la Acción Bolsa de Valores Tipo de Valor
Addex Therapeutics Ltd ADXN NASDAQ Certificado de Depósito
  Variación del Día (ptos.) Variación del Día (%) Último Precio Hora
Upgrade Icon
0.7399 9.12% 8.85 19:00:00
Precio de Apertura Precio Mínimo Precio Máximo Precio de cierre Precio Anterior
8.62 8.11 9.87 8.85 8.1101
más cotizaciones de acciones »

Noticias Recientes

Fecha Hora Fuente Noticia
29/4/202400:00GLOBEAddex Provides Update on ADX71149 Phase 2 Epilepsy Study
19/4/202400:00GLOBEAddex to Present at the Swiss Biotech Day 2024
18/4/202400:00GLOBEAddex Therapeutics Reports Full Year 2023 Financial Results..
11/4/202400:00GLOBEAddex Therapeutics to Release Full-Year 2023 Financial..
03/4/202400:00GLOBEAddex and Perceptive Launch Neurosterix with $63 Million to..
14/3/202401:00GLOBEAddex to Present at the Bio-Europe Spring 2024 Conference
31/1/202400:00GLOBEAddex Enters into At-The-Market ADS Offering Agreement with..
30/1/202416:00EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
30/1/202415:58EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
09/1/202400:00GLOBEAddex to Present at the Swiss Equities Baader Conference
05/1/202400:30GLOBEAddex to Present at Biotech Showcase™ 2024
21/12/202305:00EDGAR2Form 6-K/A - Report of foreign issuer [Rules 13a-16 and..
20/12/202305:05EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
20/12/202300:00GLOBEAddex Shareholders Approve All Resolutions at Extraordinary..
14/12/202305:05EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
14/12/202300:00GLOBEAddex Creates Treasury Shares
08/12/202313:11EDGAR2Form SC 13D/A - General statement of acquisition of..
30/11/202315:00EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
29/11/202323:15EDGAR2Form EFFECT - Notice of Effectiveness
29/11/202315:00EDGAR2Form SC 13D/A - General statement of acquisition of..
29/11/202305:27EDGAR2Form POS AM - Post-Effective amendments for registration..
29/11/202305:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
29/11/202300:00GLOBEAddex Reports Q3 2023 Financial Results and Provides..
28/11/202305:05EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
28/11/202300:00GLOBEAddex Convenes Extraordinary General Meeting
23/11/202300:00GLOBEAddex Therapeutics to Release Third Quarter 2023 Financial..
14/11/202300:00GLOBEAddex ADX71149 Epilepsy Phase 2 Study Completes Recruitment..
08/11/202305:05EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
08/11/202300:00GLOBEAddex Regains Nasdaq Listing Compliance
02/11/202301:00GLOBEAddex Announces Participation in the Bio-Europe 2023..
23/10/202305:01EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
20/10/202305:05EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
20/10/202300:00GLOBEAddex Completes ADS Ratio Change
06/10/202315:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
06/10/202315:00GLOBEAddex Announces Plan to Implement ADS Ratio Change
20/9/202305:05EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
20/9/202300:00GLOBEAddex mGlu2 NAM Cognition Program Receives €4 Million Grant
06/9/202300:00GLOBEAddex Announces Participation in the H.C. Wainwright 25th..
05/9/202305:10EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
05/9/202305:10EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
05/9/202300:00GLOBEAddex ADX71149 Phase 2 Epilepsy Study Expected to Readout..
04/9/202300:00GLOBEAddex’s Dipraglurant Development in Post-Stroke Recovery..
11/8/202315:00EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
10/8/202315:00EDGAR2Form POS AM - Post-Effective amendments for registration..
10/8/202305:31EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
10/8/202300:00GLOBEAddex Reports 2023 Half Year and Second Quarter Financial..
04/8/202300:00GLOBEAddex Therapeutics to Release Half-Year 2023 Financial..
03/8/202305:05EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
03/8/202300:00GLOBEAddex GABAB Positive Allosteric Modulator Program to Receive..
24/7/202305:05EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..

Su Consulta Reciente

NASDAQ
ADXN
Addex Therapeutics
Delayed Upgrade Clock
ADVFN Logo

México
Empresa
Negocios
Popular
Obtener la aplicación

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados